Stress response in periodontal ligament stem cells may contribute to bisphosphonate‑associated osteonecrosis of the jaw: A gene expression array analysis.

Publisher: D. A. Spandidos Country of Publication: Greece NLM ID: 101475259 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1791-3004 (Electronic) Linking ISSN: 17912997 NLM ISO Abbreviation: Mol Med Rep Subsets: MEDLINE

Original Publication: Athens, Greece : D. A. Spandidos

Bisphosphonate-Associated Osteonecrosis of the Jaw/*genetics ; Deubiquitinating Enzyme CYLD/*genetics ; Gene Expression Profiling/*methods ; Periodontal Ligament/*cytology ; Poly (ADP-Ribose) Polymerase-1/*genetics; Adolescent ; Cell Differentiation ; Cell Proliferation/drug effects ; Cells, Cultured ; Deubiquitinating Enzyme CYLD/metabolism ; Diphosphonates/adverse effects ; Gene Expression Regulation ; Healthy Volunteers ; Humans ; Models, Biological ; Oligonucleotide Array Sequence Analysis ; Periodontal Ligament/drug effects ; Periodontal Ligament/metabolism ; Protein Interaction Maps ; Stem Cells/cytology ; Stem Cells/drug effects ; Stem Cells/metabolism ; Young Adult

Gene expression alterations in periodontal ligament stem cells (PDLSCs) during bisphosphonate (BP) usage and the transcriptomic mechanism underlying BP‑related osteonecrosis of the jaw have not been fully elucidated. In the present study, human PDLSCs were isolated from adults with no history of periodontal disease, and subsequently incubated and treated with zoledronate on days 3 and 5. Subsequently, PDLSCs from all timepoints were screened using an Affymetrix Gene Expression Array. Limma differential expression analysis was performed on a normalized gene expression matrix, followed by cluster analysis, pathway and network analyses. Overall, 906 genes (352 upregulated and 554 downregulated) exhibited differential expression levels between days 0 and 5, and these were termed slow‑response genes. These slow‑response genes were enriched in cellular stress response signaling pathways (upregulated genes), as well as proliferation‑ and ossification‑associated signaling pathways (downregulated genes). Furthermore, 168 (day 3 vs. 0) and 105 (day 5 vs. 3) genes were differentially expressed between adjacent timepoints. These genes were also enriched in stress response‑ and proliferation‑associated signaling pathways, but not in ossification‑associated signaling pathways. Poly(ADP‑ribose) polymerase 1 (PARP1) and CYLD lysine 63 deubiquitinase (CYLD) had the most protein‑protein interaction partners among the slow‑response genes and were connected with both stress‑ (e.g. caspase‑1) and ossification‑associated genes [e.g. secreted phosphoprotein 1 and collagen type I α1 chain (COL1A1)]. BP treatment induced stress response‑like transcriptional alterations in PDLSCs, followed by inhibition of proliferation and ossification. These alterations may contribute to the onset of jaw osteonecrosis. PARP1 and CYLD may be two key genes involved in this pathological procedure.

Calcif Tissue Int. 2015 Sep;97(3):242-61. (PMID: 25791570)
J Oral Maxillofac Surg. 2014 Oct;72(10):1938-56. (PMID: 25234529)
Oral Maxillofac Surg. 2014 Jun;18(2):213-8. (PMID: 23512234)
OMICS. 2012 May;16(5):284-7. (PMID: 22455463)
J Clin Oncol. 2005 Aug 1;23(22):4925-35. (PMID: 15983391)
Nat Genet. 2000 May;25(1):25-9. (PMID: 10802651)
Bone. 2018 May;110:141-149. (PMID: 29408511)
Curr Pharm Des. 2010;16(11):1262-71. (PMID: 20166976)
J Oral Maxillofac Surg. 2009 May;67(5 Suppl):61-70. (PMID: 19371816)
Life Sci. 2016 Jan 15;145:152-60. (PMID: 26706287)
Mol Biol Cell. 2003 Jan;14(1):173-89. (PMID: 12529435)
Curr Med Chem. 2016;23(17):1756-74. (PMID: 25245372)
J Oral Maxillofac Surg. 2010 Nov;68(11):2837-45. (PMID: 20971371)
J Exp Med. 2010 Aug 30;207(9):1967-79. (PMID: 20713593)
Curr Drug Targets. 2015;16(4):284-94. (PMID: 25342597)
J Bone Miner Res. 2007 Oct;22(10):1479-91. (PMID: 17663640)
J Mol Cell Cardiol. 2015 Jul;84:143-53. (PMID: 25935309)
Nucleic Acids Res. 2015 Apr 20;43(7):e47. (PMID: 25605792)
Int J Oral Maxillofac Surg. 2011 Jun;40(6):605-11. (PMID: 21396799)
J Periodontol. 2014 Feb;85(2):226-33. (PMID: 23786404)
Clin Oral Implants Res. 2016 Jan;27(1):1-6. (PMID: 25371026)
Nat Immunol. 2009 Mar;10(3):241-7. (PMID: 19221555)
Oral Maxillofac Surg Clin North Am. 2015 Nov;27(4):489-96. (PMID: 26412796)
Osteoporos Int. 2008 Jun;19(6):733-59. (PMID: 18214569)
J Bone Miner Res. 2011 Aug;26(8):1871-82. (PMID: 21351151)
Nucleic Acids Res. 2017 Jan 4;45(D1):D369-D379. (PMID: 27980099)
J Oral Maxillofac Surg. 2010 Feb;68(2):243-53. (PMID: 19772941)
J Osteoporos. 2013;2013:231289. (PMID: 24455411)
Genome Res. 2003 Nov;13(11):2498-504. (PMID: 14597658)
J Oral Maxillofac Surg. 2015 Mar;73(3):377. (PMID: 25683041)
Sci Rep. 2016 Nov 23;6:37374. (PMID: 27876853)
Nat Rev Rheumatol. 2011 Nov 29;8(2):90-6. (PMID: 22124271)
Med Oral Patol Oral Cir Bucal. 2019 Jan 1;24(1):e26-e36. (PMID: 30595601)
Stem Cells Dev. 2020 Feb 1;29(3):156-168. (PMID: 31801410)
Ann Intern Med. 2006 May 16;144(10):753-61. (PMID: 16702591)

Keywords: bisphosphonate; osteonecrosis of the jaw; transcriptome; inflammation; periodontal ligament stem cells; tress response

0 (Diphosphonates)
EC 2.4.2.30 (PARP1 protein, human)
EC 2.4.2.30 (Poly (ADP-Ribose) Polymerase-1)
EC 3.4.19.12 (CYLD protein, human)
EC 3.4.19.12 (Deubiquitinating Enzyme CYLD)

Date Created: 20200725 Date Completed: 20210421 Latest Revision: 20210930

20221213

PMC7411417

10.3892/mmr.2020.11276

32705175